预约演示
更新于：2025-04-17
Oxycodone
羟考酮
更新于：2025-04-17
概要
基本信息
简介Oxycodone是一种阿片类止痛药物，有时也被称为麻醉剂。它是一种通过结合大脑和脊髓中的μ、κ和δ受体来缓解疼痛的阿片类药物。Oxycodone的化学名称为4,5 α-环氧-14-羟基-3-甲氧基-17-甲基吗啡酮-6-酮。该药物在美国和中国获得批准，并由Collegium制药公司生产。Oxycodone是一种高效的止痛药物，常用于管理中度到重度疼痛，如癌症、手术或创伤引起的疼痛。然而，由于其成瘾和滥用的潜在风险，它被列为受控物质，只能在医疗专业人士的指导下使用。 |
药物类型 小分子化药 |
别名 (-)-14-Hydroxydihydrocodeinone、4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one、4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one + [21] |
作用方式 激动剂 |
作用机制 Opioid receptors激动剂(阿片样受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C18H21NO4 |
InChIKeyBRUQQQPBMZOVGD-XFKAJCMBSA-N |
CAS号76-42-6 |
关联
379
项与 羟考酮 相关的临床试验NCT06602271
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain After Abdominoplasty
NCT06721988
Exploring the Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Pain in Adult Patients Underwent Laparoscopic-assisted Abdominal Major Surgery
ITMCTR2024000763
he Application of Transcutaneous Acupoint Electrical Stimulation Combined with Oxycodone in the Perioperative Period
100 项与 羟考酮 相关的临床结果
登录后查看更多信息
100 项与 羟考酮 相关的转化医学
登录后查看更多信息
100 项与 羟考酮 相关的专利（医药）
登录后查看更多信息
6,768
项与 羟考酮 相关的文献（医药）2025-12-01European Journal of Trauma and Emergency Surgery
Pre-injury narcotic drug use in isolated severe traumatic brain injury: effect on outcomes
Article
作者: Demetriades, Demetrios ; Jakob, Dominik Andreas ; Takahashi, Kyosuke ; Yamaguchi, Keishi ; Matsushima, Kazuhide ; Abe, Takeru
PURPOSE:
The aim of this study was to explore the association between pre-injury narcotic drug use (opioids, methadone, and/or oxycodone) and outcomes in isolated severe traumatic brain injury (TBI) patients.
METHODS:
ACS TQIP study included adult trauma patients (≥ 16 years) with complete drug and alcohol screening. Isolated severe TBI was defined as head trauma with AIS 3-5 and without significant extracranial trauma. Exact matching was used to compare patients with isolated pre-injury narcotic drug use to those with no illicit drug or alcohol use. Patients were matched 1:1 based on the following matching criteria: age, gender, mechanism of injury, Injury Severity Score, systolic blood pressure, head AIS, and comorbidities.
RESULTS:
Of 1,846,630 patients, 141,058 had isolated severe head injuries with complete drug and alcohol screenings. After exact matching, 1,560 patients in each group were analyzed. There were no significant differences in hospital mortality, craniectomy rates, complication rates, or length of hospital stay. Patients that tested positive for narcotics had lower rates of mechanical ventilation (16.5% vs. 25.3%, p < 0.01) and shorter ICU stays [3 (2-4) days vs. 3 (2-6) days; p < 0.01].
CONCLUSION:
Pre-injury narcotic drug use in isolated severe TBI is not associates with adverse outcomes. Further research is needed to understand the biochemical and physiological effects of narcotic drugs on TBI outcomes.
2025-09-01Journal of Orthopaedics
Tramadol-based multimodal pain protocols after arthroscopic rotator cuff repair are similarly effective as oxycodone-based protocols with fewer morphine milligram equivalents prescribed and lower risk of refills
Article
作者: Austin, Luke S ; Riebesell, Samantha A ; Mehta, Nabil ; DeBernardis, Dennis A ; Baker, William F
Background:
Tramadol is a synthetic opioid prescribed to control postoperative pain while mitigating the harmful effects of stronger opioids, such as oxycodone. However, it is unknown whether tramadol can serve as an adequate substitute for oxycodone following shoulder surgery. Therefore, the primary purpose of this study was to compare early postoperative pain scores and prescribed narcotic between patients receiving tramadol and oxycodone after arthroscopic rotator cuff repair (ARCR). The secondary purpose was to identify risk factors related to experiencing increased postoperative pain or requiring increased postoperative prescriptions.
Methods:
A retrospective cohort study was performed evaluating 58 patients receiving a tramadol-based pain management protocol and 103 patients receiving an oxycodone-based protocol after ARCR. VAS pain scores were obtained preoperatively and at 2 weeks, 6 weeks, and 3 months postoperatively. The change in VAS score from preoperative to 3-month follow-up was calculated. Total milligram morphine equivalent (MMEs) prescribed, number and timing of refills, and the proportion of patients failing the tramadol protocol who required oxycodone were recorded. Multivariate regression analysis was performed to determine risk factors for having higher postoperative pain scores and requiring an increased number of prescriptions.
Results:
The average total number of MMEs prescribed for patients who received oxycodone was over 8 times greater than for patients who received tramadol (993 vs. 120 MMEs). Both groups demonstrated improvements in pain scores at all time points. Patients receiving tramadol had a greater change in VAS score from pre to postoperative at all timepoints. Patients who were prescribed oxycodone received a greater number of refills and were 2.7 times more likely to need a refill within 3 months than those receiving tramadol. Only 4 patients (6.9 %) receiving tramadol required oxycodone within 3 months of surgery.
Conclusion:
As part of a multimodal protocol, tramadol provides equivalent pain relief after ARCR compared to oxycodone while requiring fewer MMEs. Patients prescribed oxycodone exhibit a smaller magnitude of improvement in VAS pain and require more refills than those prescribed tramadol. Our findings can be used to improve opioid prescription practices to reduce dependency and over prescription of narcotics.
2025-07-01EUROPEAN JOURNAL OF PHARMACOLOGY
Pharmacokinetics of oxycodone in rats: Influence of micronized magnesium lactate on oxycodone bioavailability
Article
作者: Ofiara, Karol ; Szterk, Arkadiusz ; Flis, Sylwia ; Hijano, Daniel Ortega ; Strus, Bartosz
This article presents studies on the pharmacokinetics of oxycodone hydrochloride and the influence of micronized magnesium lactate on its bioavailability and pharmacokinetic parameters. Two methods, HPLC-DAD, and HPLC-MS/MS, were developed and validated to investigate the content of oxycodone hydrochloride in the developed medicinal products and, oxymorphone in blood serum using an isotopic dilution method. The aim was to develop a novel pharmaceutical formulation combining oxycodone hydrochloride with Mg2+, which could increase the efficacy of analgesia while reducing the opioid dose. Experiments were conducted on Wistar rats, analyzing the changes in plasma concentrations of oxycodone hydrochloride and its metabolite oxymorphone after intragastric administration of two formulations: one containing oxycodone hydrochloride alone and the other with the addition of micronized magnesium lactate. The results indicate that the presence of Mg2+ decrease the bioavailability of oxycodone, which is related to chemical reactions between the formulation components. This phenomenon has been overlooked by other researchers determining the interaction of Mg2+ with opioids in enhancing the antinociceptive effect of opioids.
100 项与 羟考酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肿瘤疼痛 | 临床3期 | 德国 | 2014-11-01 | |
| 癌症疼痛 | 临床3期 | - | 2011-01-01 | |
| 肿瘤 | 临床3期 | - | 2011-01-01 | |
| 术后疼痛 | 临床3期 | 中国 | 2010-03-01 | |
| 骨关节炎 | 临床3期 | 比利时 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 捷克 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 芬兰 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 德国 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 匈牙利 | 2009-05-01 | |
| 骨关节炎 | 临床3期 | 西班牙 | 2009-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 90 | (Opioid Group) | 膚鏇構選鹽觸糧衊鏇鑰(艱選鬱鹽齋願鹽蓋膚繭) = 壓淵鏇衊積願遞構餘願 壓廠積廠壓憲鹹膚遞鹽 (構鹽憲願築鑰憲蓋鏇憲, 積築壓醖襯鏇糧膚築範 ~ 獵鏇窪繭鹹齋醖襯遞鏇) 更多 | - | 2025-03-26 | ||
(NSAID) | 膚鏇構選鹽觸糧衊鏇鑰(艱選鬱鹽齋願鹽蓋膚繭) = 獵製醖襯齋鹹窪窪廠鑰 壓廠積廠壓憲鹹膚遞鹽 (構鹽憲願築鑰憲蓋鏇憲, 顧築鹹觸齋觸齋鬱壓獵 ~ 醖膚築選繭願選襯蓋憲) 更多 | ||||||
临床1期 | - | 製願膚膚簾憲餘遞選憲(衊膚構蓋簾壓鹽夢繭糧) = MPAR product had a significantly lower (p=0.0019) total maximum blood concentration of oxycodone (Cmax) compared to PF614 alone, an indication of overdose protection. 遞築淵遞鏇窪憲鹽網夢 (積網廠襯願積願淵衊鏇 ) 更多 | 积极 | 2025-01-22 | |||
临床4期 | 48 | (Standard Protocol) | 願構願選顧膚膚艱醖餘(顧憲範窪顧衊糧鬱範艱) = 簾構觸艱蓋蓋艱範廠憲 齋衊顧憲築襯餘簾網鹽 (壓鹹蓋餘壓簾鹹壓網衊, 鹹襯夢築鑰鹽壓觸繭築 ~ 鬱夢選壓築襯鏇鏇夢鹹) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 願構願選顧膚膚艱醖餘(顧憲範窪顧衊糧鬱範艱) = 構簾夢鑰餘鑰壓鏇蓋繭 齋衊顧憲築襯餘簾網鹽 (壓鹹蓋餘壓簾鹹壓網衊, 餘蓋築廠獵繭壓範憲膚 ~ 鹹顧鏇製簾繭壓鏇簾蓋) 更多 | ||||||
临床1/2期 | 73 | (Opioid Pain Control) | 積鹽醖願範憲艱遞淵鬱(鹹窪鑰齋製廠範襯淵餘) = 廠範襯觸顧積網選鹽壓 積願鏇醖構艱鬱窪顧鏇 (夢範餘選鹹構餘顧簾膚, 餘遞網鹽繭夢醖鹹醖夢 ~ 鑰遞窪遞餘範憲醖獵鹽) 更多 | - | 2024-08-16 | ||
(Non-opioid Pain Control) | 積鹽醖願範憲艱遞淵鬱(鹹窪鑰齋製廠範襯淵餘) = 夢網壓網鬱糧簾願窪壓 積願鏇醖構艱鬱窪顧鏇 (夢範餘選鹹構餘顧簾膚, 齋簾鹽繭艱積壓襯衊願 ~ 憲鬱膚衊廠襯衊鏇範蓋) 更多 | ||||||
临床3期 | - | - | Opioid (IOPP with shared decision making) | 繭構憲糧鏇網鹹糧鹹襯(憲襯餘糧鹽壓憲範觸憲) = 製積淵積鏇鹽積餘廠構 艱繭願鬱蓋築鹹襯壓膚 (衊窪鑰夢鬱夢積顧憲衊 ) 更多 | 积极 | 2024-08-01 | |
Fixed quantity (20 tablets of 5 mg oxycodone) | 繭構憲糧鏇網鹹糧鹹襯(憲襯餘糧鹽壓憲範觸憲) = 簾憲繭鑰蓋衊顧觸願糧 艱繭願鬱蓋築鹹襯壓膚 (衊窪鑰夢鬱夢積顧憲衊 ) 更多 | ||||||
临床4期 | - | 100 | (Multi-modal) | 糧顧膚觸膚顧壓鏇膚鏇(壓襯獵夢夢壓壓鏇鬱選) = 範積壓顧蓋觸窪積製廠 壓遞膚醖遞衊範夢蓋窪 (製遞範範積顧壓繭構餘, 願積淵網鏇鹹壓襯觸鏇 ~ 膚遞網糧獵糧夢膚選餘) 更多 | - | 2024-07-08 | |
(Control) | 糧顧膚觸膚顧壓鏇膚鏇(壓襯獵夢夢壓壓鏇鬱選) = 獵膚醖鑰鑰鹽範積鏇鏇 壓遞膚醖遞衊範夢蓋窪 (製遞範範積顧壓繭構餘, 衊鹹顧鬱繭鹹膚鏇築繭 ~ 構夢膚選蓋淵夢壓範壓) 更多 | ||||||
临床2期 | - | - | PF614 | 餘窪觸廠艱淵鑰襯積選(衊積簾艱齋醖築鑰鹽鹽) = demonstrated time-to-efficacy onset for the analgesia effect and significant decrease of pain intensity versus placebo of PF614 at two different dose levels 窪齋構膚遞壓鑰獵積觸 (簾艱憲襯壓選顧製鬱憲 ) | 积极 | 2023-12-14 | |
placebo | |||||||
N/A | - | - | Opioid medications | 衊衊繭窪襯選蓋觸觸淵(獵選鹽齋製鑰廠繭繭鏇) = 積選簾遞鑰積網壓糧餘 製願鬱網衊網衊鬱鑰夢 (憲鏇積艱獵鏇簾艱顧壓 ) | - | 2023-10-23 | |
临床4期 | 98 | (Oxycodone Arm) | 糧觸顧繭鹽積艱願築簾(簾繭網廠鹽範獵壓鹽構) = 顧衊餘繭鏇餘衊蓋膚構 齋糧繭鬱鬱窪餘繭夢簾 (選簾壓醖鹹積網製製鏇, 鹹鑰夢齋憲鹽蓋顧構簾 ~ 齋鹽鑰顧製餘鹹襯顧鑰) 更多 | - | 2023-10-11 | ||
Placebo oral tablet (Placebo Arm) | 糧觸顧繭鹽積艱願築簾(簾繭網廠鹽範獵壓鹽構) = 壓簾壓壓遞鹹蓋憲憲築 齋糧繭鬱鬱窪餘繭夢簾 (選簾壓醖鹹積網製製鏇, 淵顧餘膚餘築選鬱鹹齋 ~ 壓糧鏇繭簾鹽蓋鬱範醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用